HPV-vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level

HPV and Gynecologic Cancer

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study

Lancet Glob Health.

Abbas KM, van Zandvoort K, Brisson M, Jit M

doi: 10.1016/S2214-109X(20)30022-X.

HPV and Gynecologic Cancer

Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement

JAMA.

US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW, Wong JB

doi: 10.1001/jama.2018.10897.

HPV and Gynecologic Cancer

Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy

doi: 10.1016/j.ejca.2019.04.032.

HPV and Gynecologic Cancer

Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program

JAMA Intern Med.

Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, Castle PE, Schiffman M, Kingery JD, Grewal KK, Locke A, Kinney W, Lorey TS

doi: 10.1001/jamainternmed.

HPV and Gynecologic Cancer

Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial

JAMA.

Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee M, Martin RE, Gentile L, Peacock S, Stuart GCE, Franco EL, Coldman AJ

doi: 10.1001/jama.2018.7464.

HPV and Gynecologic Cancer

Extended HPV genotyping to compare HPV type-distribution in self and provider-collected samples for cervical cancer screening

Cancer Epidemiol Biomarkers Prev.

Rohner E, Edelman C, Sanusi B, Schmitt JW, Baker A, Chesko K, Faherty B, Gregory SM, Romocki LS, Sivaraman V, Nelson JA, O'Connor S, Hudgens MG, Knittel AK, Rahangdale L, Smith JS

doi: 10.1158/1055-9965.EPI-20-0674.

HPV and Gynecologic Cancer

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis

Lancet Glob Health.

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F

doi: 10.1016/S2214-109X(19)30482-6.

HPV and Gynecologic Cancer

Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm.

Prev Med.

Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, Franco EL, Fung-Kee-Fung M, Gotlieb W, Mayrand MH, McLachlin M, Murphy J, Ogilvie G, Ratnam S

doi: 10.1016/j.ypmed.2016.11.029.

HPV and Gynecologic Cancer

Urinary HPV DNA testing as a tool for cervical cancer screening in women who are reluctant to have a Pap smear in France

J Infect.

Lefeuvre C, Pivert A, Guillou-Guillemette HL, Fabiani FL, Veillon P, Banaszuk ALD, Ducancelle A

doi: 10.1016/j.jinf.2020.05.006.

Related content

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study

Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement

Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy

Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program

Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial

Extended HPV genotyping to compare HPV type-distribution in self and provider-collected samples for cervical cancer screening

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis

Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm.

Urinary HPV DNA testing as a tool for cervical cancer screening in women who are reluctant to have a Pap smear in France